Dexamethasone sodium phosphate is under clinical development by Quince Therapeutics and currently in Phase I for Duchenne Muscular Dystrophy. According to GlobalData, Phase I drugs for Duchenne Muscular Dystrophy have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dexamethasone sodium phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexamethasone sodium phosphate overview
Quince Therapeutics overview
Quince Therapeutics (Quince) is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for rare diseases by leveraging a patient’s own biology. The company’s primary activity is the development and clinical testing of its lead product, EryDex, a pivotal Phase 3 clinical trial. EryDex is designed to treat Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease, using Quince’s proprietary autologous intracellular drug encapsulation (AIDE) technology that encapsulates a drug into a patient’s own red blood cells, potentially enhancing drug delivery and reducing adverse effects. The company’s products are primarily aimed at patients with high unmet medical needs, particularly those suffering from rare diseases like A-T. Quince is headquartered in South San Francisco, California, the US.
For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
